Message from the CSO


KAN Research Institute, Inc. was established as a wholly owned subsidiary of Eisai Co., Ltd. in April 1997. In 2006, we moved to one of Japan’s largest bio-clusters, known as the KOBE Biomedical Innovation Cluster (KBIC), and later again relocated to a new facility within KBIC in 2014. In this new environment, KAN continuously works toward achieving new drug discoveries based on sound scientific and medical knowledge in order to meet unmet medical needs. As a member of the Eisai Network Companies, it is our mission to become a human health care (hhc) company by contributing both to patients and their families.

Organelles and cells consist of protein molecules that are translated by DNA—the blueprint of life—and function as the cornerstone of life. Based on the knowledge of homeostatic mechanisms in organisms, we focus on living cells to discover new therapeutic concepts, by revealing mechanisms about homeostasis bankruptcy, a key factor in disease development and pathologic conditions.

This “Integrative Cell Biology for Medicine” research is conducted at KAN as three specialized areas: neurodegenerative diseases, the relapse and metastasis of cancers, and refractory immune diseases. We believe that this is our research advantage in that it enables us to apply the knowledge and technologies of one area to other areas and to observe one pathological condition from different disciplinary perspectives. In addition, we aim for a more innovative research approach using an integrative platform for visualizing functions in organisms during quantitative analysis.

KAN Research Institute will continue to strengthen its collaborations with academia and other organizations to create an interactive network for sharing the latest knowledge and technologies for drug discovery. We will also continue to create opportunities to connect people of diverse ideas and backgrounds to search the nature of life phenomenon and of diseases to realize better medical care.

By giving our first thoughts to patients, their families, and the realities of bedside care, we will continue to strive to fulfill unmet medical needs and contribute to society through our research activities. KAN Research Institute is grateful for your continued support and encouragement.

Toshio IMAI, Ph.D.
Chief Science Officer